Breaking Finance News

Merck (NYSE:MRK) has been upgraded from Neutral to Buy in a statement by BofA Merrill earlier today.

Boasting a price of $61.66, Merck (NYSE:MRK) traded 1.02% higher on the day. With the last close up 6.29% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Merck has recorded a 50-day average of $62.58 and a two hundred day average of $58.61. Volume of trade was down over the average, with 3,062,123 shares of MRK changing hands under the typical 9,935,220

BofA Merrill has upgraded Merck (NYSE:MRK) from Neutral to Buy in a statement released on 10/13/2016.

On 10/10/2016, Vetr Inc. released a statement on Merck (NYSE:MRK) bumped up the target price from $0.00 to $64.84 that suggested an upside of 0.02%.

Performance Chart

Merck (NYSE:MRK)

With a total market value of $0, Merck has price-earnings ratio of 34.17 with a one year low of $47.97 and a one year high of $64.86 .

A total of 20 analysts have released a research note on MRK. Two analysts rating the company a strong buy, seven analysts rating the company a buy, thirteen analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $61.60.

More About Merck (NYSE:MRK)

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *